https://ph-ksp.com/suzanne-lea-career-pivot-post-transplant-finding-new-passion-after-pulmonary-hypertension-full-transcript/ 2026-06-25T11:51:12Z PULMONARY HYPERTENSION en Suzanne Lea, Career pivot post transplant: finding new passion after pulmonary hypertension full transcript 2026-06-25T11:51:10Z Blog https://ph-ksp.com/when-science-and-ai-converge-the-evolving-landscape-of-pulmonary-arterial-hypertension-pah-care-webinar-slides-and-transcript-part-2/ 2026-06-25T11:40:12Z PULMONARY HYPERTENSION en When science and AI converge- the evolving landscape of Pulmonary Arterial Hypertension (PAH) care - webinar, slides, and transcript (part 2) 2026-06-25T10:06:05Z Blog https://ph-ksp.com/how-do-financial-conflicts-of-interest-influence-medical-prescribing-practices-medical-xpress-june-16-2026/ 2026-06-25T08:02:59Z PULMONARY HYPERTENSION en Do financial conflicts of interest influence medical prescribing practices? A Yale study published in Medical XPress, June 16, 2026 2026-06-25T08:01:57Z Blog https://ph-ksp.com/could-sotatercept-treatment-be-effective-in-patients-with-end-stage-bronchiolitis-obliterans-syndrome-after-lung-transplantation-journal-of-heart-and-lung-transplant-august-2026-edition/ 2026-06-25T07:47:54Z PULMONARY HYPERTENSION en Could sotatercept treatment be effective in patients with end-stage bronchiolitis obliterans syndrome after lung transplantation? Journal of Heart and Lung Transplant, August 2026 edition 2026-06-25T07:47:15Z Blog https://ph-ksp.com/ayotunde-omitogun-founder-of-the-cardiac-community-in-nigeria-receives-prestigious-2026-rino-aldrighetti-leadership-award-by-the-pulmonary-hypertension-association-pha-june-18-2026/ 2026-06-25T05:50:19Z PULMONARY HYPERTENSION en Ayotunde Omitogun, founder of the Cardiac Community in Nigeria, receives prestigious 2026 Rino Aldrighetti Leadership Award by the Pulmonary Hypertension Association (PHA) - June 18, 2026 2026-06-25T05:43:27Z Blog https://ph-ksp.com/inhaled-therapies-for-pulmonary-hypertension-where-we-are-and-whats-next-live-pha-webinar-on-july-23-2026-at-2-pm-edt/ 2026-06-25T05:16:01Z PULMONARY HYPERTENSION en Inhaled Therapies for Pulmonary Hypertension: Where We Are and What’s Next, Live PHA webinar on July 23, 2026 at 2 pm EDT 2026-06-25T05:16:00Z Blog https://ph-ksp.com/liquidia-lqda-presents-new-yutrepia-data-at-the-us-pulmonary-hypertension-association-phas-international-annual-conference-in-dallas-june-11-14-2026/ 2026-06-24T19:34:44Z PULMONARY HYPERTENSION en Liquidia (LQDA) presents new YUTREPIA data at the US Pulmonary Hypertension Association (PHA)s International Annual conference in Dallas, June 11-14, 2026 2026-06-24T13:56:01Z Blog https://ph-ksp.com/an-roundtable-of-us-pulmonologists-discusses-sotatercept-de-escalation-and-the-limits-of-upfront-therapy-for-pulmonary-arterial-hypertension-hcp-live-june-22-2026/ 2026-06-24T10:23:20Z PULMONARY HYPERTENSION en A roundtable of US pulmonologists discusses sotatercept, de-escalation, and the limits of upfront therapy for pulmonary arterial hypertension, HCP Live, June 22, 2026 2026-06-24T10:16:28Z Blog https://ph-ksp.com/exploring-the-therapeutic-potential-of-glp-1-receptor-agonists-in-pulmonary-arterial-hypertension-european-respiratory-journal-may-2026/ 2026-06-24T05:18:50Z PULMONARY HYPERTENSION en Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension, European Respiratory Journal, May 2026 2026-06-24T05:18:48Z Blog https://ph-ksp.com/corsair-pharma-announces-three-presentations-of-phase-1-clinical-data-for-trx-248-transdermal-system-at-the-2026-pulmonary-hypertension-association-conference/ 2026-06-24T04:59:33Z PULMONARY HYPERTENSION en Corsair Pharma Announces Three Presentations of Phase 1 Clinical Data for TRX-248 Transdermal System at the 2026 Pulmonary Hypertension Association Conference 2026-06-24T04:59:31Z Blog https://ph-ksp.com/regeneron-pharmaceuticals-expands-into-pulmonary-arterial-hypertension-with-phase-2-trial-for-regn13335/ 2026-06-24T04:48:23Z PULMONARY HYPERTENSION en Regeneron Pharmaceuticals expands Into pulmonary arterial hypertension with Phase 2 trial for REGN13335 2026-06-24T04:48:11Z Blog https://ph-ksp.com/upfront-triple-combination-therapy-with-selexipag-insights-from-a-real-world-cohort-in-chinese-patients-with-pulmonary-arterial-hypertension-frontiers-in-cardiovascular-medicine-may-21-2026/ 2026-06-23T06:03:17Z PULMONARY HYPERTENSION en Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension, Frontiers in Cardiovascular Medicine, May 21, 2026 2026-06-23T06:03:16Z Blog